JP2024156754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024156754A5 JP2024156754A5 JP2024120747A JP2024120747A JP2024156754A5 JP 2024156754 A5 JP2024156754 A5 JP 2024156754A5 JP 2024120747 A JP2024120747 A JP 2024120747A JP 2024120747 A JP2024120747 A JP 2024120747A JP 2024156754 A5 JP2024156754 A5 JP 2024156754A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- glp
- months
- analog
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197755.4A EP3628683A1 (en) | 2018-09-28 | 2018-09-28 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP18197755.4 | 2018-09-28 | ||
| JP2021517294A JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
| PCT/EP2019/076305 WO2020065064A1 (en) | 2018-09-28 | 2019-09-27 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517294A Division JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024156754A JP2024156754A (ja) | 2024-11-06 |
| JP2024156754A5 true JP2024156754A5 (enExample) | 2025-04-03 |
| JP7738136B2 JP7738136B2 (ja) | 2025-09-11 |
Family
ID=63794308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517294A Active JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
| JP2024120747A Active JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517294A Active JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220265551A1 (enExample) |
| EP (2) | EP3628683A1 (enExample) |
| JP (2) | JP7566730B2 (enExample) |
| KR (1) | KR20210069056A (enExample) |
| CN (3) | CN112771073B (enExample) |
| AU (1) | AU2019348538B2 (enExample) |
| BR (1) | BR112021005858A2 (enExample) |
| CA (1) | CA3114330A1 (enExample) |
| CL (1) | CL2021000678A1 (enExample) |
| IL (1) | IL281362A (enExample) |
| MX (1) | MX2021003271A (enExample) |
| SG (1) | SG11202102383VA (enExample) |
| WO (1) | WO2020065064A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2894629T3 (es) | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| CA3179472A1 (en) * | 2020-05-22 | 2021-11-25 | Sung Hee Hong | Liquid formulation of long-acting conjugate of glp-2 |
| WO2022129142A1 (en) * | 2020-12-16 | 2022-06-23 | Zealand Pharma A/S | Use of glp-2 analogues in patients with renal insufficiency |
| CA3231402A1 (en) * | 2021-09-10 | 2023-03-16 | Eva Horn Moller | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| IL319890A (en) | 2022-09-30 | 2025-05-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| WO2024075135A1 (en) * | 2022-10-03 | 2024-04-11 | Orbicular Pharmaceutical Technologies Private Limited | "stable injectable compositions of glp-2 peptide" |
| AU2024212236A1 (en) | 2023-01-27 | 2025-08-28 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| TW202535919A (zh) * | 2023-12-28 | 2025-09-16 | 丹麥商西蘭製藥公司 | 類升糖素肽2(glp-2)類似物之調配物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| EP1231219B1 (en) | 1996-04-12 | 2010-08-25 | 1149336 Ontario Inc. | GLucagon-like peptide-2 analogs |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US7112567B2 (en) | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| EP2119725A1 (en) * | 2005-05-03 | 2009-11-18 | Novetide Ltd. | Methods for the production of leuprolide |
| AU2006242998B2 (en) * | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| JP2009521213A (ja) * | 2005-12-24 | 2009-06-04 | ティーガスク デイリー プロダクツ リサーチ センター | トランス−１０，シス−１２オクタデカジエン酸を製造する方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| EP2051995B1 (en) * | 2006-11-08 | 2017-02-08 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| AU2007340369C1 (en) * | 2006-12-29 | 2013-05-02 | Ipsen Pharma S.A.S. | GLP-1 pharmaceutical compositions |
| MX2012013375A (es) * | 2010-05-17 | 2013-04-11 | Cebix Inc | Peptido c pegilado. |
| FR2994390B1 (fr) * | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| HUE032392T2 (en) * | 2012-11-20 | 2017-09-28 | Fresenius Kabi Usa Llc | Kaszpofunginacetát compositions |
| EP3209332B1 (en) * | 2014-10-23 | 2021-05-26 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| WO2018094404A1 (en) * | 2016-11-21 | 2018-05-24 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
-
2018
- 2018-09-28 EP EP18197755.4A patent/EP3628683A1/en not_active Withdrawn
-
2019
- 2019-09-27 CN CN201980063594.1A patent/CN112771073B/zh active Active
- 2019-09-27 JP JP2021517294A patent/JP7566730B2/ja active Active
- 2019-09-27 CN CN202510255078.6A patent/CN120204366A/zh active Pending
- 2019-09-27 US US17/276,252 patent/US20220265551A1/en active Pending
- 2019-09-27 AU AU2019348538A patent/AU2019348538B2/en active Active
- 2019-09-27 MX MX2021003271A patent/MX2021003271A/es unknown
- 2019-09-27 CN CN202410277209.6A patent/CN118267455A/zh active Pending
- 2019-09-27 EP EP19773860.2A patent/EP3856766A1/en active Pending
- 2019-09-27 KR KR1020217010775A patent/KR20210069056A/ko not_active Ceased
- 2019-09-27 CA CA3114330A patent/CA3114330A1/en active Pending
- 2019-09-27 WO PCT/EP2019/076305 patent/WO2020065064A1/en not_active Ceased
- 2019-09-27 BR BR112021005858-3A patent/BR112021005858A2/pt unknown
- 2019-09-27 SG SG11202102383VA patent/SG11202102383VA/en unknown
-
2021
- 2021-03-09 IL IL281362A patent/IL281362A/en unknown
- 2021-03-19 CL CL2021000678A patent/CL2021000678A1/es unknown
-
2023
- 2023-10-16 US US18/487,666 patent/US20240065978A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120747A patent/JP7738136B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156754A5 (enExample) | ||
| JP7202272B2 (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| CN103442695B (zh) | 肠胃外注射用肽药物的稳定制剂 | |
| ES2365410T3 (es) | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. | |
| EP1139753B1 (en) | Formulations for treating disease and methods of using same | |
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP2009506126A5 (enExample) | ||
| TW200302720A (en) | Highly concentrated stable meloxicam solutions for needleless injection | |
| JP2001525371A (ja) | Ｇｌｐ−１製剤 | |
| JP4708648B2 (ja) | レボシメンダンの医薬溶液 | |
| HU229868B1 (en) | Process for producing a pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent | |
| RU2009116531A (ru) | Способ лечения остеопороза и используемая в нем композиция | |
| KR100589878B1 (ko) | 사람 성장 호르몬을 함유한 수성 의약 조성물 | |
| WO2016180353A1 (zh) | 一种包含glp-1类似物的药物制剂及其制备方法 | |
| BRPI0616300A2 (pt) | formulaÇço aquosa de hfsh | |
| JP2022062153A5 (enExample) | ||
| US20220031612A1 (en) | Uricase gel preparation for external use, preparation method therefor and use thereof | |
| EP3373953B1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| RU2470666C2 (ru) | Фармацевтическая композиция для трансназального введения | |
| JPWO2020065064A5 (enExample) | ||
| CN102440957B (zh) | 醋酸特利加压素鼻腔喷雾剂及其制备方法 | |
| JP6862447B2 (ja) | ダニリキシンの静脈内注射用製剤 | |
| US10232009B1 (en) | Peptide for promoting wound healing, its composition and method of using the same | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| JPWO2020109526A5 (enExample) |